By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Danaher's pending $6.8 billion purchase of Beckman Coulter has cleared the last regulatory hurdle, the Washington-based conglomerate announced after the close of the market Thursday.
Registering provides access to this and other free content.
Already have an account?Login Now.
The New York Times' George Johnson muses on cancer's roots in multicellularity.
The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.
Jun Wang, the chief executive of BGI, has stepped down.
In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.